Prediction of urinary symptoms after 125iodine prostate brachytherapy.
AuthorsKelly, Karen L
Routledge, Jacqueline A
Burns, Meriel P
Logue, John P
Wylie, James P
AffiliationDepartment of Clinical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK.
MetadataShow full item record
AbstractAIMS: To evaluate the post-treatment urinary morbidity experienced by a cohort of men undergoing ultrasound-based transperineal prostate brachytherapy, as monotherapy for early stage carcinoma of the prostate. MATERIALS AND METHODS: One hundred and thirty-four consecutive patients received prostate brachytherapy between March 2000 and July 2002, and were asked to complete the International Prostate Symptom Score (IPSS) and Hospital Anxiety and Depression (HAD) questionnaires before treatment and at 1, 3, 6, 9, 12 and 18 months after implant. Data on catheterisation and surgical interventions were also recorded. Pre-treatment IPSS, dosimetry and other variables were analysed in relation to catheterisation rates and post-treatment IPSS scores at each time window. RESULTS: One hundred and eleven patients returned sufficient data for meaningful analysis. Of the patients who completed IPSS at 1 month, 85 (97%) reported deterioration in IPSS scores. This peak of symptoms, identified by a rise in median IPSS, started to improve by 3 months, and was approaching baseline by 18 months. The only significant determinants of early urinary toxicity were pre-treatment IPSS, pre-treatment prostate volume and the difficulty of implant. However, prostate volume was not significant beyond 1 month. Twenty-six patients required catheterisation at a median of 10 days after implant. Significant predictors of urinary retention were pre-treatment prostate volume and pre-treatment IPSS. Patients requiring catheterisation continued to have significantly higher IPSS at 18 months than patients who had never required a catheter. CONCLUSION: Brachytherapy was generally well tolerated, with urinary toxicity in most patients persisting for at least 3-6 months after prostate brachytherapy. Those whose pre-treatment prostate volume and IPSS were high experienced more severe urinary symptoms in the first few months.
CitationPrediction of urinary symptoms after 125iodine prostate brachytherapy. 2006, 18 (4):326-32 Clin Oncol
- Toxicity and early biochemical outcomes from 125iodine prostate brachytherapy in the UK. A prospective study.
- Authors: Henderson A, Ismail AK, Cunningham M, Aldridge S, Loverock L, Langley SE, Laing RW
- Issue date: 2004 Apr
- Urinary symptom flare following I-125 prostate brachytherapy.
- Authors: Cesaretti JA, Stone NN, Stock RG
- Issue date: 2003 Jul 15
- Urinary morbidity following ultrasound-guided transperineal prostate seed implantation.
- Authors: Gelblum DY, Potters L, Ashley R, Waldbaum R, Wang XH, Leibel S
- Issue date: 1999 Aug 1
- Temporal resolution of urinary morbidity following prostate brachytherapy.
- Authors: Merrick GS, Butler WM, Lief JH, Dorsey AT
- Issue date: 2000 Apr 1
- The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
- Authors: Neill M, Studer G, Le L, McLean M, Yeung I, Pond G, Crook JM
- Issue date: 2007 Jul-Sep